DFP-13318 Drug Asset Due Diligence Report 2026

This DFP-13318 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

130

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether DFP-13318 can convert its Small molecule drug profile and Top I biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	DFP-13318 (query alias: DFP-13318)
Modality / target	Small molecule drug; Top I; TOP1 inhibitors
Highest global status	Phase 2
Originator	Prolynx LLC
Active developers	Prolynx LLC

The MCP disease footprint includes Neoplasms, Central Nervous System Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06337630	Phase 1	Terminated	10	Primary endpoint not disclosed in English source
NCT06162351	Phase 2	Terminated	14	Primary endpoint not disclosed in English source
NCT06161519	Phase 1/2	Recruiting	146	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Phase 1/2; n=10; evaluation: Not stated in English source. Reported fields: CR = 1 Pts ; CR = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

DFP-13318 addresses Neoplasms, Central Nervous System Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 130 matched transaction record(s) under the scope “target-level comparable: Top I.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Top I records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-31	Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)	Phase 3	Financial terms not disclosed
2026-08-10	Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao	Approved	Financial terms not disclosed
2026-07-03	Sam Chun Dang Pharm expands strategic partnership with Dr. Reddy's Laboratories through liposomal drug collaboration	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination of FAK inhibitor and topoisomerase inhibitor and use thereof”. The milestone feed surfaced a patent-application signal described as “Protocol for minimizing toxicity of combination dosages and imaging agent for verification”. The milestone feed surfaced a patent-application signal described as “Slow-release conjugates of SN-38”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO